Premium
The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology
Author(s) -
van Bilsen Marc,
Patel Hitesh C.,
Bauersachs Johann,
Böhm Michael,
Borggrefe Martin,
Brutsaert Dirk,
Coats Andrew J.S.,
de Boer Rudolf A.,
de Keulenaer Gilles W.,
Filippatos Gerasimos S.,
Floras John,
Grassi Guido,
Jankowska Ewa A.,
Kornet Lilian,
Lunde Ida G.,
Maack Christoph,
Mahfoud Felix,
Pollesello Piero,
Ponikowski Piotr,
Ruschitzka Frank,
Sabbah Hani N.,
Schultz Harold D.,
Seferovic Petar,
Slart Riemer H.J.A.,
Taggart Peter,
Tocchetti Carlo G.,
Van Laake Linda W.,
Zannad Faiez,
Heymans Stephane,
Lyon Alexander R.
Publication year - 2017
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1002/ejhf.921
Subject(s) - medicine , heart failure , position paper , position statement , autonomic nervous system , translational research , intensive care medicine , cardiology , disease , neuroscience , blood pressure , pathology , heart rate , family medicine , psychology
Despite improvements in medical therapy and device‐based treatment, heart failure (HF) continues to impose enormous burdens on patients and health care systems worldwide. Alterations in autonomic nervous system (ANS) activity contribute to cardiac disease progression, and the recent development of invasive techniques and electrical stimulation devices has opened new avenues for specific targeting of the sympathetic and parasympathetic branches of the ANS. The Heart Failure Association of the European Society of Cardiology recently organized an expert workshop which brought together clinicians, trialists and basic scientists to discuss the ANS as a therapeutic target in HF. The questions addressed were: (i) What are the abnormalities of ANS in HF patients? (ii) What methods are available to measure autonomic dysfunction? (iii) What therapeutic interventions are available to target the ANS in patients with HF, and what are their specific strengths and weaknesses? (iv) What have we learned from previous ANS trials? (v) How should we proceed in the future?